LICENSED: Tandem Cytotoxic Drug Delivery & p53-Status-Independent Apoptosis Promotion

Targeted and long-lasting formulations of chemotherapeutics with low doses and few side effects.

Simple formulations to delivery two or more therapeutics to cancers with similar pharmacokinetic profiles. Easier to manufacture than nano / micro particles. Good to use in combination with immune checkpoint inhibitors.

Clinical Applications

• To sensitize the responses of cancers to chemotherapeutics.
  • rHSA-p53 synergizes with methotrexate, 5-flurouracil, paclitaxel, cisplatin, and doxorubicin in SJSA-1, MDA-MB-231, and MCF7
• To co-deliver fatty acid-modified chemotherapeutics for optimal efficacy and minimum toxicity.
  • rHSA-p53 complexed with fatty acid-modified 5-flurouracil (FA-5FU) and fatty acid-modified paclitaxel (FA-Paclitaxel, Figure 4) shows much higher cytotoxicity.
• To synergize with HER2-targeting albumin fusion protein (rHSA-(ZHER2)2) against HER2-positive cells.
  • rHSA-(ZHER2)2 is an albumin fusion protein inhibiting the proliferation of HER2-positive SKBR3 cells. It shows different mechanism from Herceptin and synergizes with rHSA-p53.

---